Search for: "Sanofi-Aventis v. Apotex"
Results 21 - 40
of 92
Sort by Relevance
|
Sort by Date
9 Nov 2011, 9:59 pm
By Donald Zuhn -- In an appeal decided last month, the Federal Circuit reversed a decision by the District Court for the Southern District of New York awarding prejudgment interest to Plaintiffs-Appellees Sanofi-Aventis, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership ("Sanofi"); affirmed the District Court's denial of a motion for leave to file a supplemental answer, affirmative defenses, and… [read post]
19 Oct 2011, 3:30 am
: Daiichi Sankyo Company Limited, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon (IPKat) (The SPC Blog) Naprelan (Naproxen) – US: Lawsuit seeks to compel FDA compliance with PDUFA user fee waiver provisions: Stat-Trade v USFDA (FDA Law Blog) OxyContin(Oxycodone) – US: Purdue Pharma files patent infringement complaint against Ranbaxy in response to Para IV certification filing (Patent Docs) Plavix… [read post]
18 Oct 2011, 10:43 am
By Dennis Crouch Sanofi-Aventis v. [read post]
18 Oct 2011, 8:31 am
” Sanofi- Aventis v. [read post]
16 Aug 2011, 11:35 pm
General Medicines Patent Pool faces licensing issues (Spicy IP) Australia: Pharmaceuticals – copyright in PIs and indirect patent infringement: Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3) (Mallesons) China: One out of three seeds in China infringes patents (IP Dragon) EU: More comments to the AG opinion in Medeva (The SPC Blog) EU: Patent term extensions – uncertainty and disharmony: an overview (The SPC Blog) India: NGO alleges… [read post]
10 Aug 2011, 4:30 am
”: a note on Neurim (The SPC blog) France: The end of the reform on the appearance of generic drugs and IPR (Class 46) Spain: A SHED OF LIGHT IN THE DARK: First Spanish decision admitting post-grant claim limitations under article 138.3 of CPE 2000: Sanofi-Aventis v. [read post]
3 Aug 2011, 3:31 am
Application fee increases by a whopping 19.4% (or almost $300K) (FDA Law Blog) US: Life sciences venture funding up 37% in second quarter (Patent Docs) Products Arava (Leflunomide) – Australia: FCA ‘evergreens’ Arava: Sanofi-Aventis Australia v Apotex (Patentology) Cambia (Diclofenac) – US: Nautilus files patent infringement complaint against Edict Pharmaceuticals in response to Para IV certification filing (Patent Docs) Cenestin… [read post]
1 Aug 2011, 8:41 am
Justice Jagot has found – generously (to Sanofi-Aventis) – that Apotex’s proposed supply of a generic leflunomide product for the treatment of arthritis would infringe the psoriasis treatment patent, and that Sanofi-Aventis is thus entitled to an injunction preventing such supply. [read post]
18 Jul 2011, 8:21 am
Lupin, Sanofi v. [read post]
18 Jul 2011, 8:21 am
Lupin, Sanofi v. [read post]
29 Jun 2011, 3:34 am
Apotex Inc. et al. [read post]
25 May 2011, 8:52 pm
From the pharmaceutical industry, amicus briefs were filed by Apotex; Sanofi-Aventis; Eli Lilly & Co.; BIO; Eisai; Johnson & Johnson; PhRMA; Teva; and GPhA. [read post]
11 Apr 2011, 12:57 pm
See Sanofi-Aventis v. [read post]
16 Mar 2011, 3:50 am
Abbott: Federal Circuit struggles to articulate a coherent standard for compliance with the Lilly written description requirement (Holman’s Biotech IP Blog) Lexapro (Escitalopram) – US: CAFC affirms obviousness of Infosint’s patent claims (IPBiz) Lotronex (Alosetron) – US: Prometheus files patent infringement suit against Roxane in response to Para IV challenge (Patent Docs) Pravastatine – Belgium/France: Post-expiry saisie-contrefaçon: Belgium and France… [read post]
18 Feb 2011, 11:47 am
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
8 Feb 2011, 10:51 pm
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New Jersey: Court precludes… [read post]
2 Feb 2011, 3:52 am
: (Perhaps) only congress knows for sure (Patent Docs) US: More on data exclusivity (Patent Docs) US: BIO supports Patent Reform Act of 2011 (PatentlyBIOtech) US: President Obama proposes, BIO agrees (Patent Docs) US: Amicus briefs in AMP v USPTO: AARP (Patent Docs) US: Orphan drug designations and applications took off in 2010 while orphan drug approvals tapered off (FDA Law Blog) US: Dexcom wins major reexamination victories over Abbott (Reexamination Alert) Products Actonel (risedronate)… [read post]
19 Jan 2011, 2:00 am
– Health Care Reform Bill (Patent Baristas) US: Academic study supports longer data exclusivity term for conventional drugs (Patent Docs) US: PTO sued after denying ‘mildly tardy’ second interim PTE request: Genetics & IVF Institute v Kappos (FDA Law Blog) US: AMP v USPTO – Appellees’ brief (Patent Docs) Products Avodart (Dutasteride) – US: GlaxoSmithKline file patent infringement complaint against Anchen following Para IV certification… [read post]
29 Dec 2010, 2:57 am
(Spicy IP) Fentanyl – Germany: Supreme Court overrules Federal Patent Court’s restrictive interpretation in case of inconsistency between preamble and claim (EPLAW) Fluvastatine – Belgium: Court of Appeal Brussels preliminarily enjoins Mylan from infringing Novartis’ patent (Kluwer Patent Blog) Glucotrol (Glipizide) – US: Alza files patent infringement complaint against Mylan following Para IV certification filing (Patent Docs) Hectorol (Doxercalciferol) – US:… [read post]
17 Nov 2010, 1:48 am
McNeil (EPLAW) Zymar (Gatifloxacin) – US: Allergan fails to secure new trial in Zymar case: Senju et al v Apotex (Patent Docs) [read post]
